Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized cancers among individuals with Li-Fraumeni syndrome (LFS). Though interval cancers remain common, Dr. Asaf Maoz, the author of the study, stated that a whole-body MRI serves as a crucial test modality for individuals with LFS that should become part of standard care, supported by practice guidelines, and covered by insurance. Read the abstract submitted to ASCO this past week and the article published online by ASCO Daily News.
